SecBot SecBot
SECBOTREPLAY Home › Report › DYN

DYN · Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER…

Dyne Therapeutics, Inc. · PRESS-RELEASE filed Mar 8, 2026 at 18:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 8, 2026 at 18:00 ET

Dyne Therapeutics announced 24-month data from its Phase 1/2 DELIVER trial showing sustained functional improvements in heart and lung function for DMD patients treated with z-rostudirsen, a therapy targeting exon 51 skipping. The results, presented at the 2026 MDA Conference, suggest potential clinical benefits beyond muscle function, including cardiopulmonary improvements compared to natural history decline.

  • 24-month data from the DELIVER trial show improvement in lung function (FVC%p), circumferential strain, and left ventricular ejection fraction vs. expected decline in natural history.
  • Z-rostudirsen demonstrated a favorable safety profile with mostly mild or moderate TEAEs; no related serious adverse events in the registrational cohort.
  • Therapy has FDA Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations for DMD amenable to exon 51 skipping.
  • Most participants at 24 months were on lower doses than the registrational 20 mg/kg, suggesting potential for even greater efficacy at full dose.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access